> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA OKs Genentech’s Vabysmo Syringe
- URL: https://www.fdaweb.com/fda-oks-genentechs-vabysmo-syringe/
- Published: 2024-07-08T12:00:00.000Z
- Updated: 2026-09-14T14:34:43.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5157285

FDA has approved Genentech’s Vabysmo (faricimab-svoa) prefilled syringe to treat wet age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion. A company [statement](https://www.gene.com/media/company-information/approvals-timeline?ref=fdaweb.com) says the prefilled 6.0 mg single-dose syringe delivers the same medicine as the 6.0 mg vial that will remain available.

Vabysmo is described as the first bispecific antibody approved for the eye. Genentech says it targets and inhibits two signaling pathways linked to some vision-threatening retinal conditions by neutralizing angiopoietin-2 and vascular endothelial growth factor.